While the EU Medical Device Regulation became effective earlier this year, questions remain about its interpretation. 

Recently, the Redica Systems virtual panel, “Changing Medical Device Regulations,” featured two industry experts providing their insights on the EU MDR and other medical device regulations: Redica Systems GMP Medical Device Expert Mark Agostino and Regulatory Mark Founder Alison Sathe. Redica Systems Senior GMP Quality Expert Jerry Chapman moderated the panel.

Webinar ad - download

Below is the first portion of a Q&A transcript from the virtual panel.

EU MDR versus MDD

Jerry Chapman

Chapman: What are the major differences between EU Medical Device Regulation (EU MDR) and its predecessor, the EU Medical Device Directive (MDD)?

Alison Sathe

Sathe: Straight away the EU MDR covers things like sterilization and cleaning products for medical devices, devices without an intended medical purpose, like aesthetic devices that were not previously covered under the MDD, and incorporates the active implantable devices as well.

And when it comes to the classification, or definition, of medical devices, some more nuance around certain parameters. Things like substances and software. You have more details surrounding those types of products. And then, of course, there is the further stratification of Class 1 products. So then you’ve got the subgroups of Class 1S, Class 1R, and Class 1M devices as well. All across the board, we are kind of seeing more detail and more rigor in terms of the documentation that you need to provide to support your marketing applications as well as your quality management system (QMS).

Mark Agostino

Agostino: In addition to what Alison talked about, I think a couple of additional areas note is that the person responsible for regulatory compliance is not stipulated under the EU MDR. That is a big change compared to the EU MDD—having someone accountable for providing oversight over your QMS. Having that level of oversight to identify issues, gets into the premise of the EU MDR and why it was created, which is to sort of hold manufacturers accountable including senior management to issues as they arise to a product out there in the marketplace.

Another change from the MDD is the function of Notified Bodies and the legal responsibility of notified bodies. Under MDD, Notified Bodies were able to provide sort of consulting services to manufacturers and help them sort of understand that pathway to get their product to the market. Well, that is really no longer. And I think that is also contributing to the angst and challenges for manufacturers to navigate the pathway of MDR…not having that ability to consult on a regular basis for your Notified Bodies during the various elements of the regulation.

EU MDR Requirements for QMS

Chapman: What do you consider some of the challenges of the EU MDR when it comes to the QMS?

Agostino: For me, one of the challenges is device classification as Alison mentioned. In regards to your QMS, you now have to account for that risk and that change in risk for your devices.

Also, there are still elements that have not been fully fleshed out. Expert panels still need to be created and implemented. The intent of these expert panels is to provide a level of standardization for various device types and to help establish a level of consistency in interpreting the EU MDR. Additionally, there are competent authorities who actually do not think EU MDR has gone far enough, which means that QMS are going to need to potentially account for whatever changes that these authorities come up with over the coming years. Manufacturers will also have to understand their economic operators and related QMS requirements. 

[Editor’s Note: For more on the EU MDR and economic operators, read Mark Agostino’s article, “EU MDR and Economic Operators for Medical Devices.”]

Sathe: I fully agree with this. And I think to your point about the breadth of the EU MDR, one of the things I see folks do when they’re looking to start their pathway is jump into the technical documentation. I actually caution, make that Step 2. People see the EU MD and they say, “I am going to just start with my General Safety and Performance Requirements (GSPRs), and I am going to go from there.”

That is great, you need to do that. Your technical documentation will need to be updated. But I think starting with that QMS piece is really important because you need to make sure that you have that infrastructure in place for not just updating your technical file, but the ongoing activities that are required.

It is really a paradigm shift for a lot of folks in that there is just more detail required both in the technical documentation premarket, but throughout the total product lifecycle (TPLC). If you do start with your QMS, it actually makes that second piece [the technical documentation] a lot easier because then you have the form, the format, the structure that is going to support everything going into your technical file. 

[Editor’s Note: For more on EU MDR challenges, check out the video clip below.]

Chapman: What are some of the pitfalls and the new paradigms companies should look out for? Such as things like transition timing, staffing and resource allocation, and the regulatory, quality, and clinical areas.

Sathe: I think that goes back to that infrastructure piece, it is not just going to be one technical person that is going to be able to handle all of your updates. It is not just a quality person. We are seeing more and more involvement from all of the various aspects of the TPLC.

When you are looking at things like risk management, particularly in combination products, you need to really develop robust risk management with the TPLC that includes all of the various voices—your clinician or your chief medical officer, your engineers, your quality staff, your regulatory staff. All of those folks are going to be required for review and approval of all of the various documentation that is going to go in to fulfill those GSPRs and your postmarket requirements.

Agostino: To further add on to that, just to me, I think some of the challenges that manufacturers are experiencing are due to varying interpretations of the regulations by Notified Bodies. I think that is also part of the challenge, understanding from a resource and timeline standpoint how to get your product to market. From people that I have talked to and who deal with this here in Europe, I think they want that level of consistency, going from one Notified Body to the other. 

This transcript has been lightly edited for clarity.

[Editor’s Note: Part II of this series looks at postmarket surveillance requirements.]

[Related: The webinar recording is now available for download here.]

Webinar ad - download

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.